Capricor Insider Sells Shares Amid Stock Decline
Karen Krasney, EVP and General Counsel of Capricor Therapeutics (NASDAQ: CAPR), sold approximately $732,000 worth of shares following the exercise of stock options. The transaction involved selling all newly acquired shares immediately after purchase at a weighted average price of $30.38 per share. This sale reduced Krasney's direct ownership in Capricor by 44%, leaving her with around 30,547 shares valued at approximately $929,000 based on the June 25 market close. Capricor Therapeutics is a clinical-stage biotechnology company focused on developing cell and exosome-based therapies for rare diseases such as Duchenne muscular dystrophy. The stock has experienced significant volatility in recent months, with shares down about 30% year-to-date through July 24 after gaining over 200% the previous year. The sale was conducted under a prearranged trading plan (10b5-1), which is typically used to mitigate insider trading concerns. While such transactions are not uncommon, they may raise questions among investors about future stock performance and company developments.
Tickers: $CAPR